A simulation of the visual impact of AMD

Altos Biologics said it expects to launch its Eylea (aflibercept) biosimilar ALT-L9 by 2025, following recruitment of 431 neovascular age-related macular degeneration (AMD) patients to its phase 3 study. 

Altos previously reported successful phase 1 trials of ALT-L9, where it was shown to have similar safety and efficacy profiles to Regeneron Pharmaceuticals’ Eylea. The company said it considers Eylea “quite an expensive therapy” and claims a less expensive biosimilar will enable the market to increase by reaching more patients who cannot afford Eylea. Projections show around 720 million people worldwide will need AMD treatment by 2025, it said.